Scar Management
Part of the ukdermatologist.co.uk Knowledge Hub
A Comprehensive Evidence-Based Guide for Patients
By Prof. Vishal Madan MBBS (Hons), MD, FRCP
Consultant Dermatologist & Laser Surgeon | GMC No. 6036936
HCA The Wilmslow Hospital | Circle The Beaumont Hospital Bolton | Same-day Doctor Clinic Manchester
This patient information guide explains how scars form, why some scars become raised or problematic and which evidence-based treatments may help. It covers hypertrophic scars, keloids, atrophic scars, silicone therapy, intralesional injections, laser treatments and combination scar management approaches.
Section 1: Epidemiology and Pathophysiology
1.1 How Common Are Problem Scars?
Scarring is one of the most significant yet underrecognised challenges in dermatology. Annually, more than 100 million new scars develop worldwide, with about 15% becoming excessive scars that need medical treatment.
| Scar Type | Prevalence |
|---|---|
| All new scars annually worldwide | > 100 million per year |
| Develop into excessive or problematic scars | ~15% of all new scars |
| Hypertrophic scars post-surgery | 38-68% of surgical patients |
| Hypertrophic scars post-burns | Up to 90% of burn patients |
| Keloid scars worldwide prevalence | ~11 million individuals |
| Keloids in Black and Hispanic populations | 4.5-16% prevalence |
| Keloids in Caucasian populations | 0.09% prevalence |
The clinical impact of problem scars extends well beyond cosmesis:
- Pain and pruritus, or itch: affects 20-40% of patients with hypertrophic or keloid scars.
- Functional impairment: particularly when scars cross joint lines or are located on the hands, neck or face.
- Psychological distress: anxiety, depression and impaired body image are well-documented consequences.
- Reduced quality of life: measured across multiple validated instruments.
Monstrey S, et al. JPRAS. 2014;67:1017-1025.
1.2 The Biology of Scar Formation: A Three-Phase Process
Understanding the formation of scars is key to exploring treatment options. All scars, whether typical or abnormal, arise from the wound-healing process. This process involves three overlapping but separate phases and any disruption in these stages can cause abnormal scarring.
Shirakami, Eri, Sho Yamakawa and Kenji Hayashida. Burns & Trauma 8 (2020). Durani P et al. Avotermin. Int J Low Extrem Wounds. 2008;7:160-8.
Phase 1: Inflammatory Phase (Days 1-7)
Platelet activation occurs immediately after tissue damage, forming a fibrin clot to halt haemorrhage. Chemotactic factors are released, recruiting inflammatory cells to the wound site. Neutrophils arrive first, followed by macrophages. Both play key roles in clearing debris and initiating repair. Cytokines, including TGF-β, PDGF and IL-1, orchestrate the subsequent healing response.
Phase 2: Proliferative Phase (Days 7-21)
Fibroblast activation and migration into the wound occurs. These cells are the principal producers of the extracellular matrix (ECM), which forms the structural basis of scar tissue. Collagen synthesis begins, with type III collagen predominating in early scar tissue. Angiogenesis and vessel maturation supply oxygen and nutrients and granulation tissue fills the wound space.
Phase 3: Remodelling Phase (3 Weeks to Over 1 Year)
This is the most important phase in determining the final appearance and quality of the scar. The balance between matrix metalloproteinases, collagen-degrading enzymes and their tissue inhibitors governs net collagen turnover. Type III collagen is progressively replaced by the stronger type I collagen over months. Myofibroblasts undergo programmed cell death. Blood vessels similarly regress, explaining why scars fade from red to pale over time.
In abnormal scarring, including hypertrophic scars and keloids, this remodelling is disrupted. Fibroblasts remain activated, collagen continues to accumulate and the scar fails to mature normally.
Key Insight from Prof. Madan
The remodelling phase lasts over a year, which is why scar treatment initiated early and maintained consistently produces the best outcomes. Scars do not stop changing at the point they become visibly stable.
Section 2: Classification of Scars
2.1 Normal vs Abnormal Scars
Not all scars are pathological. A normal mature scar is flat, pale to skin coloured, asymptomatic and non-progressive. Abnormal scars are characterised by raised, firm, erythematous, symptomatic or expanding tissue. The two principal forms of abnormal scarring are hypertrophic scars and keloids. Distinguishing between them is clinically critical, as their management differs.
2.2 Hypertrophic Scars vs Keloids: Key Differences
| Feature | Hypertrophic Scar | Keloid |
|---|---|---|
 |
 |
|
| Wound boundary | Remains within original wound margins | Extends beyond original wound margins |
| Spontaneous regression | May improve over 12-24 months | Rarely regresses without treatment |
| Recurrence after surgery alone | Lower risk with adjuvant therapy | 45-100%; surgery alone is contraindicated |
| Progression | Stabilises over months to years | Can expand for years after injury |
| Symptoms: itch or pain | Common | Often severe |
| Skin type predisposition | All skin types | Predominantly Fitzpatrick IV-VI |
| High-risk locations | Flexural areas and areas of tension | Earlobes, sternum, deltoid and jaw |
| Genetic component | Uncommon | 5-10% familial; chromosomes 2 and 7 |
A keloid, unlike a hypertrophic scar, should be viewed as a fibroproliferative disorder rather than simply an exaggerated scar response. It invades the surrounding normal skin at its periphery, often continues to grow for years after the precipitating injury and has a pronounced tendency to recur after surgical excision. This distinction fundamentally informs the treatment strategy.
2.3 Atrophic and Other Scar Types
Beyond hypertrophic and keloid scars, the dermatologist must also recognise:
- Atrophic scars: depressed below the surrounding skin surface due to collagen loss. Common sequelae of acne, chickenpox and trauma. Treated with fractional laser resurfacing, microneedling, subcision and dermal fillers.
- Post-inflammatory hyperpigmentation (PIH): pigmentary change following skin inflammation or injury, more prevalent in darker skin types. This is not strictly a scar, but it frequently accompanies scars and requires specific management.
- Contracture scars: result from wound healing across a joint or flexure, producing tightening that restricts movement. Most seen post-burn. May require surgical release with or without skin grafting.
Section 3: Risk Stratification
3.1 Who Is at Highest Risk?
Identifying patients at high risk of abnormal scarring before surgery or a skin procedure is one of the most important preventative steps a clinician can take. Prof. Madan assesses risk across three domains.
Patient-Related Risk Factors
- Fitzpatrick skin types IV-VI: significantly increased risk of keloid and hypertrophic scar formation.
- Age 11-30 years: peak incidence of keloid formation; risk decreases in older adults.
- Personal history of keloids: one of the strongest predictors of future keloid development.
- Family history of keloids: 5-10% of keloid patients have a first-degree relative with keloids.
- Hormonal factors: pregnancy and puberty are associated with exacerbation of keloid activity.
Location-Related Risk Factors
- Earlobes: the most common site for keloid formation, often following ear piercing.
- Sternum and central chest: high-tension, sebaceous-gland-rich skin with a high propensity for keloids.
- Deltoid region: particularly high risk, including after vaccination.
- Pubic area: a recognised keloid-prone zone.
- Fusion zones: anatomical areas where embryonic tissue planes merge, such as the jaw line and pre-sternal region.
- High-mobility areas: skin over joints or areas of repetitive movement.
Wound-Related Risk Factors
- Burns: the highest-risk wound type; up to 90% develop hypertrophic scarring.
- Wounds under high tension: particularly important on the trunk and over joints.
- Infected wounds: chronic inflammation prolongs the proliferative phase of healing.
- Poor surgical technique: inadequate layered closure, excessive wound-edge trauma or excessive tension.
- Delayed wound closure: longer healing times correlate with worse scarring.
Clinical Advice from Prof. Madan
If you have a personal or family history of keloids, always inform your surgeon, dermatologist or therapist before any elective procedure, including aesthetic treatments, cosmetic surgery, ear piercing or tattooing.
A preventative management plan should be agreed before the procedure takes place.
Section 4: Clinical Assessment of Scars
4.1 The Vancouver Scar Scale (VSS)
Objective measurement of scar severity is essential for clinical decision-making and for tracking treatment response over time. The Vancouver Scar Scale is the most widely used validated assessment tool, adopted as the primary outcome measure in most scar clinical trials.
| Parameter | Score Range | Description |
|---|---|---|
| Pigmentation | 0 normal to 3 deeply pigmented | Colour of the scar relative to surrounding normal skin |
| Vascularity | 0 normal to 3 purple or violaceous | Blood vessel activity; red or pink indicates active scarring |
| Pliability | 0 normal to 5 contracture | Flexibility and softness of scar tissue |
| Height | 0 flat to 3 > 5mm elevation | How raised the scar is above the surrounding skin surface |
| Total | 0 best to 13 worst | Lower scores indicate better scar quality |
4.2 Additional Assessment Tools
Patient and Observer Scar Assessment Scale (POSAS): incorporates both observer assessment and the patient's own experience of their scar, including pain, itch, colour, stiffness, thickness and irregularity.
Manchester Scar Scale (MSS): a simpler clinical tool used in some centres for quick assessment.
Standardised clinical photography: Prof. Madan documents every scar at baseline and at each follow-up visit, using consistent lighting, distance and positioning. This provides objective visual evidence of treatment progress.
4.3 When Should I Seek Specialist Assessment?
Early specialist assessment is strongly recommended if any of the following apply:
- The scar remains raised, firm, red or itchy for more than 3 months after wound healing.
- The scar is visibly expanding beyond the original wound boundary.
- You have a personal history of keloid formation and are planning any elective procedure.
- The scar is causing pain, restricted movement or psychological distress.
- Over-the-counter silicone products have not produced adequate improvement after 3-6 months of consistent use.
- You have a darker skin phototype and are concerned about the risk of scarring following injury or surgery.
Waiting is rarely beneficial. Early treatment, initiated within the first few months of scar formation, consistently yields superior outcomes compared with delayed intervention.
Section 5: Prevention Strategies
5.1 Evidence-Based Prevention
For patients identified as high risk, prevention should begin as early as possible, ideally at the time of wound closure.
Silicone Therapy: First-Line Prevention
- Commence silicone gel or sheets as soon as the wound is fully epithelialised, typically 2 weeks post-surgery.
- Silicone sheets: wear for 12-24 hours per day and continue for a minimum of 2-6 months.
- Silicone gel: apply twice daily to clean, dry skin and allow to dry before applying a dressing.
- Evidence level: high, Level I.
Momeni M, et al. Burns 2009;35:70-4. van der Wal et al. Plast. Reconstr. Surg. 2010;126:524-31.
Wound Tension Reduction
- Layered deep suture closure to place tension on the deeper dermis rather than the skin surface.
- Adhesive wound-closure strips after suture removal to maintain wound-edge apposition.
- Avoidance of early suture removal in high-risk sites.
Sun Protection
- Immature scar tissue is highly susceptible to UV-induced hyperpigmentation.
- Apply SPF 50+ broad-spectrum sunscreen to the scar for at least 12 months after wound closure.
- Physical protection is recommended when sun avoidance is not possible.
Compression Therapy
- Particularly valuable for post-burn wounds and larger surgical scars on the trunk or limbs.
- Custom-fitted pressure garments should provide sustained compression of 20-25 mmHg.
- Worn for 23 or more hours per day for 6-18 months, depending on scar severity.
Behaviour Modification for High-Risk Patients
- Avoid elective ear piercings, tattoos or cosmetic procedures at known keloid-prone sites.
- Seek pre-procedure counselling before elective surgery if there is a personal or family history of keloids.
- Report any new raised, itchy wound to a dermatologist promptly.
Section 6: Treatment: Evidence Hierarchy and Overview
6.1 The Evidence Base: Systematic Review Findings
The evidence base for scar management has expanded considerably. A comprehensive analysis of 68 randomised controlled trials involving over 3,000 patients provides a rigorous foundation for treatment recommendations.
| Treatment | Efficacy / Outcome |
|---|---|
| Intralesional 5-FU and Triamcinolone acetonide | 87.7% improvement, highest recorded |
| Silicone sheets or gel for hypertrophic scars | 62% mean improvement |
| Triamcinolone acetonide monotherapy | 64% improvement; 50-90% response rate |
| Silicone for keloids as monotherapy | 34% mean improvement |
| Silicone and compression garments | 37-44% improvement |
| Pulsed Dye Laser monotherapy | 55.4% improvement |
| Fractional CO₂ laser monotherapy | 47.1% improvement |
| Non-ablative fractional laser monotherapy | 41.6% improvement |
| Physical therapy alone | ~30% improvement |
| Topical treatments alone, non-silicone | ~30% improvement |
Core Treatment Principle
Combination therapy consistently and significantly outperforms monotherapy.
Efficacy hierarchy: intralesional treatments > laser > physical modalities > topical treatments.
Prof. Madan selects treatment combinations individually based on scar type, skin phototype, scar location, symptom profile and patient preference.
Section 7: First-Line Treatment: Silicone Therapy
7.1 Mechanism of Action
Silicone is the most extensively studied non-invasive treatment for hypertrophic and keloid scars. Its mechanism of action is multifactorial. It creates a hydrated, occlusive microenvironment at the scar surface, reduces capillary activity, downregulates fibroblast activity and helps regulate temperature at the wound surface.
7.2 Products and Protocol
| Product Form | Protocol |
|---|---|
| Silicone gel sheets | Apply directly over closed scar; wear 12-24 hours per day; wash daily. |
| Silicone gel topical | Apply a thin layer to scar; allow to fully dry before dressing; use twice daily. |
| Minimum duration | 2-6 months of continuous, consistent use. |
| When to start | Once wound is fully epithelialised, approximately 2 weeks post-surgery. |
7.3 Efficacy Data
There is a 62% average improvement in VSS scores for hypertrophic scars, based on Level I evidence. Keloids show a 34% average improvement when treated with monotherapy. When combined with compression garments, the improvement ranges from 37% to 44%.
Momeni M, et al. Burns 2009;35:70-74. van der Wal et al. Plast. Reconstr. Surg. 2010;126:524-531.
Section 8: Intralesional Corticosteroid Injections
8.1 Triamcinolone Acetonide (TAC)
Intralesional corticosteroid injection remains a cornerstone of scar management and carries the highest grade of clinical evidence. Triamcinolone acetonide is the most widely used agent.
8.2 Mechanism of Action
TAC reduces localised inflammation within scar tissue by blocking pro-inflammatory cytokine production. It directly inhibits fibroblast proliferation, reduces collagen synthesis and cross-linking and helps soften the scar matrix.
8.3 Clinical Protocol
| Parameter | Detail |
|---|---|
| Agent | Triamcinolone acetonide |
| Concentration range | 2.5-40 mg/mL, titrated to scar type and skin phototype |
| Injection interval | Every 4-6 weeks |
| Typical course | 3-6 injections for initial response; maintenance as needed |
| Anaesthesia | Topical EMLA cream 60 minutes prior or ethyl chloride spray |
| Technique | Intralesional injection directly into scar substance; raised wheal technique |
8.4 Efficacy and Side Effects
- Response rates: 50-90% for hypertrophic and keloid scars.
- Recurrence rates post-treatment: 9-50%, underscoring the importance of maintenance therapy and combination approaches.
- Telangiectasia: approximately 24%.
- Hypopigmentation: approximately 20%, of particular concern in patients with darker skin phototypes.
- Skin atrophy: approximately 18%, more likely with higher concentrations or superficial injection.
- Injection-site pain: common and mitigated with topical anaesthetic.
Prof. Madan uses a precise intralesional technique and carefully calibrates TAC concentration to the individual patient’s skin phototype and scar characteristics.
Ledon JA, et al. Dermatol Surg. 2013;39:1745-1757.
Section 9: Combination Intralesional 5-FU and Triamcinolone
9.1 The Most Effective Intervention in the Literature
The combination of intralesional 5-fluorouracil and triamcinolone acetonide is the most effective intervention identified in the systematic review evidence base, achieving an 87.7% improvement on validated scar scoring tools.
9.2 How Does 5-FU Work in Scar Treatment?
5-fluorouracil is an antimetabolite agent that, when injected intralesionally, acts directly on keloid and hypertrophic scar fibroblasts. It inhibits fibroblast proliferation by blocking RNA and DNA synthesis and induces apoptosis in activated scar fibroblasts. When used with TAC, the two agents work together.
9.3 Protocol and Evidence
- Typical ratio: 5-FU 50 mg/mL combined with TAC 10-40 mg/mL in varying proportions.
- Injection interval: every 2-4 weeks.
- Number of sessions: typically 4-8.
- Evidence: 87.7% improvement in clinical scar score, Level I.
- Adverse effects: transient stinging or burning, hypopigmentation and rare tissue necrosis at high concentrations.
This combination is now considered the gold-standard intralesional treatment for established keloids and refractory hypertrophic scars at Prof. Madan’s clinics, provided there are no contraindications.
Section 10: Laser Treatment for Scars
10.1 Overview of Laser Platforms
Below are the four principal laser platforms for scar management, each targeting distinct scar characteristics.
| Laser | Target / Primary Indication | Efficacy Monotherapy |
|---|---|---|
| Pulsed Dye Laser, PDL 595nm | Vascular component; erythema, itch and pain | 55.4% improvement |
| Fractional CO₂ Laser 10,600nm | Scar texture, thickness, pliability and LADD | 47.1% improvement |
| Er:YAG Laser | Alternative to CO₂ for texture and LADD | 41.6% improvement |
| Long-pulsed Nd:YAG 1064nm | Vascular targeting in darker skin types | Evidence emerging |
10.2 Pulsed Dye Laser (PDL): VBeam
The pulsed dye laser at 595nm targets oxyhaemoglobin in the superficial vasculature of the scar. This selective photothermolysis of scar blood vessels produces reduction in scar erythema, improvement in itch and pain and softening of scar texture over the treatment course.
PDL is the laser of first choice for red, symptomatic, vascular hypertrophic and keloid scars and for erythematous post-surgical scars.
Stephanides S, August PJ, Ferguson JE, Madan V. Laser Therapy 20(4):279-286 (2011).
10.3 Fractional CO₂ Laser (UltraPulse)
Fractional ablative laser resurfacing with CO₂ delivers columns of controlled thermal injury into the scar tissue. This stimulates new collagen production and remodelling, enhances texture, thickness and flexibility and creates microchannels for Laser-Assisted Drug Delivery.
10.4 Best Laser Combinations from 2024 Network Meta-Analysis
| Combination | Best For |
|---|---|
| Fractional CO₂ and intralesional 5-FU via LADD | Best overall VSS reduction; thickness and pliability |
| Fractional CO₂ and intralesional TAC | Best improvement in pliability |
| PDL and fractional CO₂ | Best for combined vascular and textural components |
| PDL and intralesional TAC | Refractory keloids, Prof. Madan’s published protocol |
Foppiani JA et al. Aesthetic Plastic Surgery. 2024;48:3988-4006.
10.5 Laser Safety in Darker Skin Types
Skin phototype stratification is one of the most critical considerations in scar laser therapy. Fitzpatrick types I-III can usually be treated with the full range of laser wavelengths. Fitzpatrick types IV-VI have a significantly higher risk of post-inflammatory hyperpigmentation and hypopigmentation with certain wavelengths.
Long-pulsed Nd:YAG 1064nm is preferred for vascular targeting in darker skin types because its wavelength has lower affinity for epidermal melanin. Conservative starting parameters, mandatory test patches and longer inter-treatment intervals are used.
Prof. Madan has extensive experience treating patients across the full Fitzpatrick spectrum and takes a tailored, conservative approach to laser treatment in patients with darker skin phototypes.
Section 11: Laser-Assisted Drug Delivery (LADD)
11.1 What Is LADD?
Laser-Assisted Drug Delivery combines the structural effects of fractional laser treatment with the pharmacological action of a topically applied therapeutic agent. By creating precise microscopic channels in the scar tissue, the laser enhances penetration and bioavailability of agents that would otherwise have limited penetration through the fibrotic scar surface.
11.2 How LADD Works
- A fractional laser, such as fractional CO₂, is applied to the scar surface, creating thousands of microscopic channels.
- A therapeutic agent, such as triamcinolone acetonide or 5-FU, is applied topically immediately after laser treatment.
- The microchannels allow deep penetration of the agent into the scar tissue.
- The laser channels close within 24 hours, trapping the drug within the scar matrix.
11.3 Clinical Evidence: 2024 Systematic Review
LADD: Key Findings
- Efficacy: equivalent to direct intralesional injection.
- Pain: significantly less painful than needle injection.
- Superiority: better than topical application alone.
- Ideal for needle-phobic patients, large scar areas and paediatric patients.
- Evidence level: moderate-high, Level II.
Bernabe RM et al. J Burn Care Res. 2024;45:590-600.
11.4 Optimal LADD Protocol
| Protocol Element | Recommendation |
|---|---|
| Laser choice | Er:YAG, preferred for superficial delivery, or fractional CO₂ |
| Agent options | Triamcinolone acetonide, 5-fluorouracil or verapamil |
| Application timing | Apply agent immediately after laser treatment while channels are open |
| Number of sessions | 4-8 sessions at monthly intervals |
| Post-treatment care | Standard post-laser wound care; SPF protection |
| Advantage for patients | Substantially less painful than intralesional injection |
Section 12: Adjuvant and Emerging Therapies
12.1 Physical Modalities
| Modality | Evidence / Efficacy |
|---|---|
| Compression garments, 20-25 mmHg, 23+ hours per day | ~29.9% improvement as monotherapy |
| Massage therapy alone | ~9.5% improvement; limited as standalone |
| Compression and massage combined | Up to 44% improvement |
| Cryotherapy | Best combined with intralesional injections; intralesional cryotherapy preferred for keloids |
| Pressure earrings after earlobe keloid excision | Standard adjuvant; reduces recurrence |
12.2 Surgical Excision: Important Caution
Critical: Surgery for Keloids
Surgical excision alone for keloids carries a recurrence rate of 45-100%.
Surgery is never appropriate as a standalone treatment for keloid scars.
Excision is reserved for functional impairment or very large keloids where bulk reduction facilitates adjuvant therapy.
All keloid surgery must be combined with adjuvant therapy, such as intralesional injections, radiotherapy, silicone or laser.
12.3 Emerging and Investigational Therapies
Biological and Pharmacological Agents
- Transforming Growth Factor-β3, Avotermin / Juvista: recombinant cytokine investigated in clinical trials.
- ACE inhibitors: investigated for anti-fibrotic properties via TGF-β pathway modulation.
- Verapamil: used intralesionally or via LADD to inhibit fibroblast collagen synthesis.
- Bleomycin: used intralesionally in refractory keloids where other treatments have failed.
Regenerative Approaches
- Platelet-Rich Plasma: variable evidence with heterogeneous study quality.
- Fat grafting / lipofilling: adipose-derived stem cells may modulate scar fibrosis and improve texture and pliability.
- Microneedling: stimulates controlled collagen remodelling and enhances topical drug delivery.
- Mesenchymal Stem Cells: investigational; early data suggest modulation of inflammatory and fibrotic pathways.
Section 13: Clinical Management Algorithms
13.1 Hypertrophic Scar Algorithm
- Prevention: silicone therapy commenced at 2 weeks post-wound healing; compression if applicable; sun protection.
- First-line treatment: silicone and intralesional TAC every 4-6 weeks for 3-6 sessions; reassess at 3 months.
- If incomplete response: add PDL for vascular component and/or fractional CO₂ LADD for thickness and pliability.
- Refractory cases: intralesional 5-FU and TAC combination; combination laser treatment.
- Maintenance: ongoing silicone, annual review and photography at each visit.
13.2 Keloid Treatment Algorithm
- Risk assessment: Fitzpatrick skin type, location, personal/family history and prior treatment response.
- First-line treatment: intralesional 5-FU and TAC every 3-4 weeks; silicone therapy and compression garments if applicable.
- Laser adjunct: PDL for erythema and symptoms; fractional CO₂ LADD for fibrotic bulk.
- Refractory keloids: combination PDL and intralesional TAC; consider bleomycin or verapamil intralesionally.
- Surgical consideration: only for functional impairment and only with immediate post-operative adjuvant therapy.
- Maintenance: long-term monitoring and repeat intralesional treatment at first signs of recurrence.
Take-Home Principle
For keloids: never stop at one treatment. The natural history of keloids is to recur. A maintenance plan is as important as the initial treatment course.
Section 14: Frequently Asked Questions
Will my scar disappear completely?
Complete eradication of a scar is not achievable with current treatments. The realistic goal is meaningful clinical improvement: a flatter, softer, paler, less symptomatic scar that is less conspicuous and has less functional or psychological impact.
The best outcomes are achieved by commencing treatment early, using evidence-based combination approaches, maintaining consistent compliance and planning for long-term maintenance.
How many treatment sessions will I need?
| Treatment | Typical Sessions / Duration |
|---|---|
| Intralesional injections | 3-6 sessions at 4-6-week intervals initially; maintenance as needed |
| Silicone therapy | Minimum 2-6 months of daily continuous use |
| Pulsed Dye Laser | 3-6 sessions at 4-8 week intervals |
| Fractional CO₂ laser | 3-6 sessions; collagen remodelling continues for months post-treatment |
| LADD | 4-8 sessions at monthly intervals |
Treatment plans are reviewed and adjusted at each visit using the Vancouver Scar Scale and clinical photography.
Are scar treatments painful?
- Silicone gel or sheets: non-invasive and painless.
- Intralesional injections: brief sharp stinging; topical EMLA anaesthetic cream can significantly reduce discomfort.
- Pulsed Dye Laser: felt as a rubber-band snap sensation against the skin.
- Fractional CO₂ laser: more intense; topical anaesthetic is standard.
- LADD: considerably less painful than direct intralesional injection.
How long does it take to see results?
- Intralesional injections: softening and flattening typically begin within 4-6 weeks.
- Silicone: early improvement may be apparent from 4-8 weeks; optimal results at 3-6 months.
- PDL laser: reduction in redness and symptoms often noticeable after 2-3 sessions.
- Fractional CO₂: texture and pliability improvements develop gradually over 3-6 months.
- LADD: progressive improvement over a 4-8 session course.
Scar remodelling is a slow biological process. The full benefit of a treatment course may not be apparent for 6-12 months after completion.
Does skin type affect which treatment is best for me?
Yes. Skin phototype is one of the most important factors in treatment selection and in managing the risk of pigmentation complications. Fitzpatrick types I-III can usually access the full range of laser wavelengths. Fitzpatrick types IV-VI require more conservative laser parameters, mandatory test patches and careful prioritisation of appropriate treatments.
Prof. Madan is experienced in treating patients of all ethnicities and skin types and takes a fully personalised approach.
Can I prevent a scar from forming after surgery?
Prevention is always preferable to treatment, particularly for patients at high risk. Effective prevention includes silicone gel or sheets from around 2 weeks post-surgery, SPF 50+ sun protection for at least 12 months, adhesive wound closure strips after suture removal, compression garments where appropriate and prophylactic planning for patients with known keloid tendency.
Section 15: Consulting Prof. Vishal Madan
15.1 What to Expect at Your Consultation
At your initial consultation, Prof. Madan will:
- Take a thorough clinical history, including the origin of the scar, prior treatments, skin phototype, family history and psychological effects.
- Evaluate the scar clinically and with standardised photography.
- Categorise the scar type and assess the risk of progression or recurrence.
- Discuss all relevant, evidence-based treatment options, their effectiveness and potential results.
- Develop a personalised treatment plan, emphasising combination therapies when appropriate.
- Set realistic expectations for the timeline, outcomes and degree of improvement achievable.
Book a Consultation
If you are concerned about a raised, painful, itchy, thickened or cosmetically troubling scar, a specialist dermatology consultation can help identify the scar type and the most appropriate treatment options.